May | 28 | 2024
Press Release

Remix Therapeutics™ Announces Participation in Jefferies Healthcare Conference

Watertown, Mass. (May 28, 2024) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that its management team will host one-on-one meetings with investors at the Jefferies Healthcare Conference taking place on Tuesday, June 4, 2024 in New York City. For those investors interested in scheduling a one-on-one meeting with the Remix management team, please contact your Jefferies representative.

About Remix Therapeutics Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix’s innovative therapeutic approach has the potential to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:

Media Contact:
Lissette Steele
lissette.steele@vergescientific.com
202-930-4762 ext. 409

Investor Contact:
Will O'Connor 
Stern Investor Relations 
will.oconnor@sternir.com 
212-362-1200  

Back to News
Media Contact
LISETTE STEELE
Verge Scientific Communications
Investor Contact
WILL O’CONNOR
Stern Investor Relations